Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Spermatogenesis01:41

Spermatogenesis

Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male reproductive...
Testes: Histology01:27

Testes: Histology

A tough, fibrous membrane, the tunica albuginea, covers the testes, extending inward to form fibrous partitions or septa, dividing them into internal compartments called lobules. Each lobule has 1 to 3 tightly coiled seminiferous tubules where sperm production occurs. These tubules merge into a tubular network at the back of the testis, known as the rete testis. It connects to 15 to 20 efferent ductules, leading to the epididymis.
The spermatogenic cells, responsible for producing sperm, are...
Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Double trouble: Co-occurrence of testosterone deficiency and body fatness associated with all-cause mortality in US men.

Clinical endocrinology·2017
Same author

Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men.

Andrology·2014
Same author

Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.

International journal of impotence research·2014
Same author

Dutasteride in men receiving testosterone therapy: a randomised, double-blind study.

Andrologia·2014
Same author

Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens.

Andrologia·2013
Same author

Access to information and expectations of treatment decisions for prostate cancer patients--results of a European survey.

European journal of cancer care·2013
Same journal

What Is Hidden Behind Growth Hormone Deficiency? The Neuroradiologist's Perspective.

Frontiers of hormone research·2024
Same journal

Fugitive Acromegaly: A Historical, Clinical, and Translational Perspective.

Frontiers of hormone research·2024
Same journal

Perioperative Mobility Assessment of Acromegalic Patients Undergoing Endoscopic Endonasal Resection of Pituitary Adenomas Using Digital Phenotyping.

Frontiers of hormone research·2024
Same journal

Treatment with Long-Acting Somatostatin Analogues in Patients with Acromegaly: When and How.

Frontiers of hormone research·2024
Same journal

Bone, Metabolic and Mental Detrimental Effects of GHD: Reasons Underlying Replacement Therapy in Adults.

Frontiers of hormone research·2024
Same journal

Pituitary Acrogigantism: From the Past to the Future.

Frontiers of hormone research·2024
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Testosterone and prostate safety.

A Morgentaler1, C Schulman

  • 1Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass., USA.

Frontiers of Hormone Research
|November 18, 2008
PubMed
Summary
This summary is machine-generated.

Testosterone therapy does not increase prostate cancer risk. Low testosterone levels, however, are linked to higher prostate cancer risk, necessitating regular monitoring for men on testosterone therapy.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Related Experiment Videos

Last Updated: Jun 28, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Area of Science:

  • Endocrinology
  • Urology
  • Oncology

Background:

  • Historical belief: Higher testosterone (T) promotes prostate tissue growth.
  • Recent evidence challenges this long-standing assumption regarding T therapy risks.

Purpose of the Study:

  • To evaluate the association between testosterone therapy and prostate health.
  • To assess the risk of prostate cancer and benign prostatic hyperplasia (BPH) with T therapy.

Main Methods:

  • Review of smaller clinical trials and population-based longitudinal studies.
  • Analysis of data on serum T, intraprostatic T, and dihydrotestosterone (DHT) levels.

Main Results:

  • Studies consistently fail to support increased prostate cancer risk or BPH exacerbation with T therapy.
  • Exogenous T does not appear to increase intraprostatic T or DHT, suggesting a saturation effect.
  • Low serum T is associated with increased prostate cancer risk and more aggressive features.

Conclusions:

  • Available evidence indicates testosterone therapy is safe for the prostate.
  • Regular prostate cancer monitoring is recommended for men on T therapy due to overlapping risk factors.